Tomatidine suppresses osteoclastogenesis and mitigates estrogen deficiency-induced bone mass loss by modulating TRAF6-mediated signaling.
Hu B, Sun X, Yang Y, Ying Z, Meng J, Zhou C, Jiang G, Li S, Wu F, Zhao X, Zhu H, Wu H, Cai X, Shi Z, Yan S.
Hu B, et al. Among authors: jiang g.
FASEB J. 2019 Feb;33(2):2574-2586. doi: 10.1096/fj.201800920R. Epub 2018 Oct 4.
FASEB J. 2019.
PMID: 30285579
Therefore, tomatidine could be a novel candidate for the treatment of osteoclast-related disorders, including osteoporosis.-Hu, B., Sun, X., Yang, Y., Ying, Z., Meng, J., Zhou, C., Jiang, G., Li, S., Wu, F., Zhao, X., Zhu, H., Wu, H., Cai, X., Shi, Z., Yan, S. ...
Therefore, tomatidine could be a novel candidate for the treatment of osteoclast-related disorders, including osteoporosis.-Hu, B., Sun, X., …